MX2016002307A - Tratamiento para el cancer. - Google Patents
Tratamiento para el cancer.Info
- Publication number
- MX2016002307A MX2016002307A MX2016002307A MX2016002307A MX2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer treatment
- individual
- cancer
- treatment
- trichostatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere en general al tratamiento del cáncer. Una modalidad de la invención proporciona un método de tratamiento de cáncer en un individuo, comprendiendo el método: administrar al individuo una cantidad eficaz de tricostatina A (TSA).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361869039P | 2013-08-22 | 2013-08-22 | |
PCT/US2014/052209 WO2015027121A2 (en) | 2013-08-22 | 2014-08-22 | Cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016002307A true MX2016002307A (es) | 2016-06-15 |
Family
ID=51794948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016002307A MX2016002307A (es) | 2013-08-22 | 2014-08-22 | Tratamiento para el cancer. |
Country Status (12)
Country | Link |
---|---|
US (5) | US20160199323A1 (es) |
EP (2) | EP3616754A1 (es) |
JP (4) | JP2016528297A (es) |
KR (5) | KR20210127821A (es) |
CN (2) | CN105579101A (es) |
AU (4) | AU2014308700A1 (es) |
CA (1) | CA2921036A1 (es) |
CL (1) | CL2016000397A1 (es) |
EA (1) | EA037667B1 (es) |
ES (1) | ES2755983T3 (es) |
MX (1) | MX2016002307A (es) |
WO (1) | WO2015027121A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210127821A (ko) * | 2013-08-22 | 2021-10-22 | 반다 파마슈티칼즈, 인코퍼레이티드. | 암 치료 |
WO2021016203A1 (en) * | 2019-07-19 | 2021-01-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target |
WO2023168201A1 (en) * | 2022-03-01 | 2023-09-07 | Vanda Pharmaceuticals Inc. | Trichostatin a (tsa) sensitivity in the treatment of tumors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4218478A (en) * | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
CA1265431A (en) | 1985-01-08 | 1990-02-06 | Roderick John Macdonald | Electrode device for flare stack ignitor |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
US20020183388A1 (en) * | 2001-02-01 | 2002-12-05 | Gudas Lorraine J. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
CA2529840A1 (en) * | 2003-06-27 | 2005-01-06 | Astellas Pharma Inc. | Therapeutic agent for soft tissue sarcoma |
ES2555994T3 (es) | 2004-05-21 | 2016-01-12 | The Board Of Trustees Of The University Of Arkansas System | Uso de perfiles de expresión génica para predecir la supervivencia en un paciente con cáncer |
WO2007067516A2 (en) * | 2005-12-06 | 2007-06-14 | Duke University | Multiple myeloma |
CN101495111A (zh) | 2006-05-26 | 2009-07-29 | 细胞基因公司 | 在联合治疗中使用免疫调节化合物的方法和组合物 |
CA2574531C (en) * | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
TWI662964B (zh) * | 2012-06-04 | 2019-06-21 | 美商製藥有限責任公司 | 布魯頓氏酪胺酸激酶抑制劑之結晶形式 |
KR20160033780A (ko) | 2013-08-22 | 2016-03-28 | 반다 파마슈티칼즈, 인코퍼레이티드. | 다발성 골수종 치료 |
KR20210127821A (ko) * | 2013-08-22 | 2021-10-22 | 반다 파마슈티칼즈, 인코퍼레이티드. | 암 치료 |
-
2014
- 2014-08-22 KR KR1020217033186A patent/KR20210127821A/ko not_active IP Right Cessation
- 2014-08-22 CA CA2921036A patent/CA2921036A1/en active Pending
- 2014-08-22 JP JP2016536469A patent/JP2016528297A/ja active Pending
- 2014-08-22 AU AU2014308700A patent/AU2014308700A1/en not_active Abandoned
- 2014-08-22 CN CN201480046624.5A patent/CN105579101A/zh active Pending
- 2014-08-22 US US14/912,077 patent/US20160199323A1/en not_active Abandoned
- 2014-08-22 CN CN201910836673.3A patent/CN110585184A/zh active Pending
- 2014-08-22 EA EA201690445A patent/EA037667B1/ru unknown
- 2014-08-22 MX MX2016002307A patent/MX2016002307A/es unknown
- 2014-08-22 KR KR1020177032020A patent/KR20170126018A/ko not_active IP Right Cessation
- 2014-08-22 EP EP19201777.0A patent/EP3616754A1/en active Pending
- 2014-08-22 ES ES14789436T patent/ES2755983T3/es active Active
- 2014-08-22 KR KR1020217002758A patent/KR102315528B1/ko active IP Right Grant
- 2014-08-22 WO PCT/US2014/052209 patent/WO2015027121A2/en active Application Filing
- 2014-08-22 KR KR1020167004630A patent/KR20160033779A/ko active Application Filing
- 2014-08-22 KR KR1020237010047A patent/KR20230047203A/ko not_active Application Discontinuation
- 2014-08-22 EP EP14789436.4A patent/EP3036007B1/en active Active
-
2016
- 2016-02-22 CL CL2016000397A patent/CL2016000397A1/es unknown
-
2018
- 2018-05-15 US US15/980,644 patent/US10265282B2/en active Active
-
2019
- 2019-03-18 US US16/357,249 patent/US11078289B2/en active Active
- 2019-05-08 JP JP2019088425A patent/JP2019167351A/ja active Pending
- 2019-11-06 AU AU2019261718A patent/AU2019261718A1/en not_active Abandoned
-
2021
- 2021-03-16 JP JP2021042699A patent/JP2021105005A/ja active Pending
- 2021-06-28 US US17/359,986 patent/US11667718B2/en active Active
- 2021-11-03 AU AU2021261882A patent/AU2021261882B2/en active Active
-
2022
- 2022-03-30 AU AU2022202183A patent/AU2022202183B2/en active Active
-
2023
- 2023-03-22 JP JP2023045826A patent/JP2023088996A/ja active Pending
- 2023-04-25 US US18/306,601 patent/US20230257471A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502075A1 (en) | Treatment of cataplexy | |
HK1219486A1 (zh) | 用於治療癌症的涉及抗密蛋白 的抗體的療法 | |
HK1213925A1 (zh) | 用於治療癌症的涉及抗密蛋白 抗體的組合療法 | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
EP2944323A4 (en) | MEANS FOR THE TREATMENT OF TUMORS, USE AND METHOD THEREFOR | |
MX2015014590A (es) | Tratamiento de cancer con dihidropirazino-pirazinas. | |
NZ722600A (en) | Methods of treating mild brain injury | |
MX2017000306A (es) | Metodos para tratar hipotension. | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
MX2016002308A (es) | Tratamiento del mieloma multiple. | |
PH12014502065A1 (en) | Vesicular formulations | |
MX2016002307A (es) | Tratamiento para el cancer. | |
RS63738B1 (sr) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera | |
BR112016014099A2 (pt) | método de tratamento de feridas | |
SI2976360T1 (sl) | Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka | |
MX2017013669A (es) | Composiciones para el tramiento del cancer. | |
NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
UA86338U (ru) | Способ лечения беременных с гестационным диабетом |